The first half of 2026 marks a pivotal moment for China's offline retail pharmacy industry, which is undergoing a deep market consolidation. The total number of pharmacies nationwide has fallen from a peak of 706,000 to 673,000, with a net closure of 22,000 stores in 2025 and an additional 803 closures across six major listed chains in H1 2026. This signals a definitive end to the era of aggressive expansion, pivoting the sector toward stock optimization and efficiency-driven competition.

Mid-year financial reports reveal a pronounced divergence among top players. While three giants with revenues exceeding RMB 10 billion — Dashenlin, Yifeng, and Laobaixing — have achieved simultaneous growth in both revenue and profit, Yixintang and Jzj are navigating a deep adjustment phase with declining revenues. Meanwhile, Guoda Pharmacy sits at the bottom of a profit recovery after significant store closures. The industry's Matthew effect is intensifying as inefficient capacity exits and market share concentrates among leaders.

Divergent Financial Performance and Expansion Strategies Among Listed Retailers

Listed pharmacy chains have formed a clear tiered structure by revenue scale. The first tier maintains steady growth, with Dashenlin leading the sector at RMB 13.991 billion, up 3.46% year-on-year, followed by Yifeng Pharmacy with RMB 12.13 billion in revenue, a 3.48% increase, and Laobaixing at RMB 10.998 billion, up 2.07%. All three have reversed consecutive declines from 2024 and 2025, achieving growth despite industry-wide pressure.

In contrast, second-tier companies are generally losing momentum. Yixintang Pharmaceutical Group Co., Ltd. recorded revenue of RMB 8.467 billion, down 5.02%, while Jzj Chain Drugstore Corporation's revenue fell 6.14% to RMB 4.183 billion. Guoda Pharmacy saw revenue decline 2.4% to RMB 10.227 billion. Only Shuyu Pingmin bucked the trend with an 8.86% revenue increase to RMB 5.314 billion, driven by regional store densification, though its profit quality failed to keep pace.

Profitability metrics show leaders outpacing revenue growth with effective cost controls. Yifeng Pharmacy posted the highest net profit attributable to shareholders at RMB 964 million, a 9.51% increase, achieving an 8.81% net margin. Dashenlin followed with RMB 927 million, up 16.10% — the fastest growth among frontrunners — lifting its net margin to 7.16%. Laobaixing reported RMB 447 million, a 12.30% rise, successfully reversing two consecutive years of declines and recovering its net margin to 4.76%. The primary driver for all three is stringent expense management, with selling expense ratios dropping to 28.36%, 25.77%, and 25.96% respectively, down 1.62, 0.87, and 1.53 percentage points year-on-year.

Second-tier profitability remains precarious. Yixintang achieved net profit of RMB 257 million, a modest 2.88% growth with a 3.09% net margin. Shuyu Pingmin suffers from profitless growth, with net profit falling 28.90% to RMB 25.776 million and a razor-thin 0.52% margin. Jzj saw net profit drop 25.87% to RMB 54 million, while Guoda Pharmacy is most strained, generating only RMB 13 million in net profit from its RMB 10.2 billion revenue — a 19.74% decline — hovering near breakeven.

In terms of sales efficiency, Dashenlin leads with direct-store sales of RMB 2,195.30 per square meter, up 1.3% from RMB 2,166.96 last year, with its southern China stronghold hitting RMB 2,374.87. Yifeng Pharmacy records daily efficiency of RMB 54.94 per square meter, translating to roughly RMB 1,648 monthly, a 2.3% improvement. Laobaixing achieves RMB 49 daily, up 4.3%, though still trailing the leaders, explaining its comparatively lower net margin. Shuyu Pingmin, a regional player, manages RMB 45 per day, significantly below national peers due to intense competition and lower average transaction values in Shandong.

Store expansion strategies diverge sharply amid sector shrinkage, forming three distinct paths. Dashenlin is the only major player aggressively expanding, adding a net 968 stores in H1 to reach 18,726, including 273 self-built, 146 acquired, and 696 franchised outlets, while closing 147 underperforming direct stores. Its focus has shifted to densifying existing provincial markets rather than cross-region expansion.

Yifeng and Laobaixing adopt a prudent adjustment approach. Yifeng added a net 408 stores, comprising 211 self-built, 11 acquired, and 263 franchised, while voluntarily closing 77 inefficient locations, ending with 15,239 stores. Laobaixing grew by 202 net stores, including 217 new direct and 389 net franchised additions, closing 177 low-performing units to finish at 15,177. Both prioritize quality over quantity, focusing on core regions to boost per-store output and profitability.

Yixintang, Jzj, and Guoda pursue contraction and optimization. Yixintang shut 297 stores, bringing its total down 240 to 10,872. Jzj continued its fine-tuned approach, reducing its footprint by a net 8 stores. Guoda cut 246 stores to 7,975, having shed over 2,400 locations across two years of major closures. These strategies reflect each company's strategic choices based on their strengths and regional positions; market leaders leverage brand and supply chain advantages for high-quality growth, while regional players trim operations to protect profit bases.

Peak Store Count Signals Integration Opportunity for Pharmacy Sector

Looking ahead, the past two decades of unchecked expansion have concluded. National pharmacy numbers fell from 684,000 in 2024 to 656,000 by end-2025, a net reduction of 27,000, with another 10,000 closures in H1 2026 — the first sustained negative growth in a decade. Notably, this wave of closures is driven not by independent pharmacies but by small and mid-sized chains; of the nearly 20,000 stores closed from Q4 2024 to Q3 2025, 84.5% were from this segment, with mid-sized chains of 300-500 stores hit hardest due to their lack of scale benefits or flexibility.

Contrary to expectations, industry consolidation has not rapidly increased chain density. The national chain ratio actually dropped from 62.3% in 2024 to 56.23% in 2025, as mid-sized chains closed faster than independent pharmacies exited.

Looking forward 3-5 years, the competitive landscape is forming. Within the first tier, Dashenlin and Yifeng are best positioned to emerge as industry duopolists. Dashenlin relies on its scale and southern stronghold, while Yifeng leads in profit quality through refined management. Both employ a dual "self-operated + franchised" model to accelerate penetration into lower-tier markets, absorbing space vacated by exiting mid-sized chains. Data suggests Laobaixing lags in profitability and operational efficiency, compounded by compliance issues, putting it at a competitive disadvantage. The second tier faces harsher challenges, with further divergence likely. Mergers and acquisitions will dominate the integration phase, potentially making regional leaders acquisition targets that gain new life by joining national networks.

2026 marks a turning point for the offline pharmacy industry. Beneath the wave of closures lies an inevitable transition from rough growth to high-quality development. Following this period of adjustment, the sector will emerge healthier and more sustainable. For enterprises, this is simultaneously the worst and best of times — as inefficient competitors exit and market space frees up, market leaders face a historic opportunity to consolidate and strengthen their positions.